A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2017
At a glance
- Drugs Dusigitumab (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.